Log in
Create new account
home
boards
job center
archives
company monitor
cp wire
device news
pharmagather
advertise
contact us
Home
ocrelizumab
News
The Top 10 Phase III Failures of 2010
Fierce Biotech
Antisoma
ASA404
AstraZeneca
clinical trials
diabetes
dimebon
Eli Lilly
Ipsen
Medivation
Merck
Novartis
Novelos Therapeutics
ocrelizumab
Pfizer
Recentin
rheumatoid arthritis
Roche
Sanofi
semagacestat
taspoglutide
Vical
vicriviroc
zibotentan
»
3 comments
News
A Potential Blockbuster Bites the Dust. Should You Worry?
Motley Fool
Biogen Idec
ocrelizumab
rheumatoid arthritis
Roche
»
2 comments
News
Roche Holding, Biogen to halt arthritis program
Marketwatch
arthritis
Biogen Idec
ocrelizumab
Roche
»
1 comment
News
Roche arthritis drug meets goal, safety issues linger
Reuters
arthritis
ocrelizumab
Roche
»
11 comments
News
Roche, Genentech and Biogen Idec announce positive results from first phase III trial of ocrelizumab
PR-Canada
Biogen Idec
Genentech
ocrelizumab
Roche
»
121 comments
News
Roche arthritis drug effective in late-stage study
Reuters
arthritis
ocrelizumab
Roche
»
7 comments
news tags
Abbott Laboratories
Amgen
Arena Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
biotech
Boston Scientific
Bristol-Myers Squibb
cancer
Celgene
China
Dendreon
diabetes
earnings
Eli Lilly
Europe
FDA
generics
Genzyme
GSK
hepatitis C
investors
JNJ
lawsuits
layoffs
M&A
Management
Medtronic
Merck
Novartis
obesity
patents
Pfizer
prostate cancer
Roche
Sanofi
Teva Pharmaceuticals
vaccines
Vivus
more tags
Yahoo! Finance
Quote for ABT